Dear colleagues, as we all know that NTRK positivity is rare but across the many solid tumours. Target therapy are now available and entrectinib is one of them . I am happy to share with you for a development ,we got succeed to make centre for Entrectinib CU for Rajasthan under the following rules for selecting an appropriate patients. The inclusion criteria for the Compassionate Use Program are as below: Patients eligible for Entrectinib CU to fulfill all criteria mentioned below: – Have exhausted all other available or acceptable or potentially effective standard therapies – Documented NTRK fusion-positive, locally advanced or metastatic solid tumors who have not received prior TRK inhibitors, have either progressed following prior therapies or have no acceptable or potentially effective standard therapies (NTRK fusion positivity must be confirmed prior to receiving entrectinib). – Documented ROS1 fusion-positive NSCLC with brain metastases who have not received prior ROS1 inhibitor or have no acceptable or potentially effective standard therapies (ROS1 fusion positivity must be confirmed prior to receiving entrectinib) Patient must not have received prior crizotinib All mechanisms to acquire crizotinib should be fully exhausted (e.g. international pharmacy or clinical trials) according to local law and regulations.